Your session is about to expire
← Back to Search
Other
PAC-1 for Uveal Melanoma
Phase 1 & 2
Waitlist Available
Led By Arkadiusz Dudek, MD, PhD
Research Sponsored by Arkadiusz Z. Dudek, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to a maximum of 15 months
Awards & highlights
Study Summary
This trial will test the safety and effectiveness of a new cancer drug given with another cancer drug that is already approved.
Eligible Conditions
- Uveal Melanoma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to a maximum of 15 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to a maximum of 15 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Phase 1b: Determine Maximum Tolerated Dose (MTD)
Phase 2: Progression Free Survival at 3 Months
Secondary outcome measures
Assess Adverse Events
Overall Survival (OS)
Phase 2: Duration of Response (DoR)
+1 moreSide effects data
From 2019 Phase 1 trial • 28 Patients • NCT037960137%
Arthropod bite
4%
Cough
4%
Nasal congestion
100%
80%
60%
40%
20%
0%
Study treatment Arm
Form A Reference Formulation
Form C Test Formulation
Trial Design
1Treatment groups
Experimental Treatment
Group I: Study Treatment ArmExperimental Treatment2 Interventions
Phase 1b will determine the MTD of PAC-1 in combination with entrectinib. Study treatment will include: PAC-1 will be taken orally on Days 1-21 and Entrectinib will be taken orally on Days 1-28 of each 28-day cycle. Treatment will continue until disease progression (based on RECIST 1.1 criteria), unacceptable toxicity, subject withdrawal of informed consent, or subject death either from progression of disease, the therapy itself, or from other causes.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Entrectinib
2014
Completed Phase 2
~360
PAC-1
2015
Completed Phase 1
~50
Find a Location
Who is running the clinical trial?
Vanquish Oncology, Inc.Industry Sponsor
2 Previous Clinical Trials
66 Total Patients Enrolled
Genentech, Inc.Industry Sponsor
1,541 Previous Clinical Trials
568,025 Total Patients Enrolled
HealthPartners Regions Cancer Care and Frauenshuh Cancer Care CentersUNKNOWN
Share this study with friends
Copy Link
Messenger